Azithromycin Pediatric Dose — Antimicrobial Therapy
Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is commonly used in pediatric practice for the treatment of community-acquired pneumonia, atypical respiratory infections (including Mycoplasma pneumoniae and Chlamydia trachomatis), and other susceptible bacterial infections. Its favorable oral bioavailability and once-daily dosing make it a practical choice across a wide range of pediatric ages.
Pediatric Dosing
Dosing differs by age group and is administered either intravenously or orally (IV/PO):
Children ≥6 Months
- Day 1: 10 mg/kg IV/PO (single dose)
- Days 2–5: 5 mg/kg IV/PO every 24 hours
Infants <6 Months
- Days 1–5: 10 mg/kg IV/PO every 24 hours (flat dosing throughout the course)
Adult Reference Doses
- Day 1: 500 mg; Days 2–5: 250 mg daily
Worked example (≥6 months) — 20 kg child: Day 1: 20 × 10 mg/kg = 200 mg; Days 2–5: 20 × 5 mg/kg = 100 mg daily. Worked example (<6 months) — 4 kg infant: Days 1–5: 4 × 10 mg/kg = 40 mg daily. Consult institutional protocol regarding maximum single-dose capping.
Indications and Clinical Context
Azithromycin is indicated for the treatment of mild-to-moderate community-acquired pneumonia (CAP), including atypical organisms such as Mycoplasma pneumoniae and Chlamydia pneumoniae, as well as pharyngitis, skin and soft-tissue infections in penicillin-allergic patients, and pertussis prophylaxis or treatment. In pediatric CAP guidelines, azithromycin is a recommended agent for school-age children and adolescents where atypical pathogens are suspected, consistent with PALS and IDSA/PIDS CAP guidance. The modified flat-dose regimen for infants under 6 months reflects pharmacokinetic differences and specific indications such as Chlamydia trachomatis pneumonia in this age group.
Administration and Monitoring
Azithromycin may be administered intravenously or orally depending on clinical status and tolerability. Oral formulations (suspension or tablet) are preferred when the patient can tolerate enteral intake. IV administration should be given as a slow infusion (typically over 60 minutes) to minimize infusion-related reactions such as pain and local inflammation; rapid IV bolus is not recommended. Monitor for QTc prolongation, particularly in patients with pre-existing cardiac conditions or those receiving concomitant QT-prolonging agents. GI adverse effects (nausea, vomiting, abdominal cramping) are the most commonly reported side effects.
- Avoid in patients with known hypersensitivity to azithromycin or other macrolides
- Use with caution in patients with hepatic impairment
- Infantile hypertrophic pyloric stenosis (IHPS) has been reported in neonates and young infants — weigh risks and benefits carefully in this population
- Consult institutional protocol for maximum single-dose limits and IV concentration guidelines
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.